Biotech: Page 2


  • novavax shot
    Image attribution tooltip
    Carsten Koall via Getty Images
    Image attribution tooltip

    Activist investor pushes case against Novavax leadership

    Shah Capital, which owns a 7.5% stake in Novavax, called for shareholders to vote against re-electing three of the vaccine maker’s director nominees.

    By Meagan Parrish • May 3, 2024
  • View of Moderna headquarters
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna ends gene editing alliance with Metagenomi

    Metagenomi said the companies’ decision to part ways followed a “strategic prioritization” undertaken by Moderna, which has made several investments in gene editing research in recent years.

    By Kristin Jensen • May 2, 2024
  • Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Explore the Trendline
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    COVID-19 vaccines

    The urgency of the pandemic’s first two years is giving way to questions of how to sustain public health responses and prepare for what could come next. In the U.S., health officials are urging booster shots and preparing for private sector distribution of vaccines.

    By BioPharma Dive staff
  • A portrait of Kevin Marks, CEO of Delphia Therapeutics.
    Image attribution tooltip
    Permission granted by Delphia Therapeutics
    Image attribution tooltip
    Emerging biotech

    Delphia starts up with $67M to make a new type of cancer drug

    The startup is developing medicines designed to overstress cellular pathways to the point tumor cells die, an approach the biotech calls “activation lethality.”

    By May 2, 2024
  • Image attribution tooltip
    National Cancer Institute, NIH
    Image attribution tooltip

    BridgeBio spinout launches with $200M for KRAS cancer drugs

    The company, BridgeBio Oncology Therapeutics, has one drug in the clinic and hopes to soon advance two other candidates.

    By Updated May 2, 2024
  • A 3D illustration of a nerve cell on a black background
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Reunion raises over $100M to build a better psychedelic drug

    The funding will help Reunion pay for a mid-stage study testing its most advanced medicine — essentially a synthetic version of the hallucinogenic psilocin — in women with postpartum depression.

    By May 2, 2024
  • A scientist works in a laboratory at Enlaza Therapeutics.
    Image attribution tooltip
    Permission granted by Enlaza Therapeutics
    Image attribution tooltip

    Enlaza gets JP Morgan, Regeneron backing for covalent biologics

    The funds will help the cancer-focused startup Enlaza bring several candidates toward human testing in the next few years, its CEO said.

    By April 30, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip
    Emerging biotech

    Repertoire pivot pays dividends with Bristol Myers deal

    The alliance validates the new direction pursued by Repertoire, a startup that cut staff and switched CEOs in 2022 after research on personalized cell therapies disappointed.

    By April 29, 2024
  • An illustration of an inspection laboratory in a medicine production factory.
    Image attribution tooltip
    alvarez via Getty Images
    Image attribution tooltip

    BioMarin drops drug programs in pipeline cull

    The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.

    By Kristin Jensen • April 25, 2024
  • A photo of the exterior of Regeneron.
    Image attribution tooltip
    Permission granted by Regeneron
    Image attribution tooltip
    Gene editing

    Regeneron expands in gene editing with Mammoth deal

    “With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.

    By April 25, 2024
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen: Don’t expect any big acquisitions this year

    While the company is eager to diversify, CEO Chris Viehbacher said any near-term dealmaking would likely focus on collaborations and early-stage assets.

    By April 24, 2024
  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna turns to AI to change how its employees work

    An expanded partnership with OpenAI is helping Moderna embed custom-built AI chatbots in a wide range of research and business processes.

    By April 24, 2024
  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Biogen to invest more in launch of Alzheimer’s drug Leqembi

    Growing demand has convinced Biogen that it's worth expanding the sales force around Leqembi by 30%.

    By April 24, 2024
  • This image depicts the podcast series image for Allucent's BioPharma Dive series, "Partner for Progress: Strategies for Biotech Success"
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Allucent

    [Podcast] Partner for Progress: Strategies for Biotech Success

    In this three-part podcast series, hear from seasoned experts from Allucent as they discuss a range of topics, including how small and mid-sized companies can take a more strategic approach to pharmacovigilance, a regulatory & development roadmap for ADCs and RDCs, and pre-MAA/NDA inspection readiness.

    Updated April 29, 2024
  • A photo of CureVac headquarters in Tuebingen, Germany
    Image attribution tooltip
    Courtesy of CureVac AG
    Image attribution tooltip

    CureVac to cut costs in restructuring

    The mRNA vaccine maker, which has lost most of its value since early 2021, is undergoing an “organizational redesign” that will eliminate 150 positions.

    By Kristin Jensen • April 24, 2024
  • A person uses laboratory equipment in Endeavor Biosciences' offices.
    Image attribution tooltip
    Permission granted by Endeavor Biosciences
    Image attribution tooltip
    Emerging biotech

    Endeavor pulls in $132M to back cancer, lung disease drugs

    Led by the founder of a biotech Celgene acquired for $7 billion, the startup is developing two prospects that originated in the labs of other drugmakers.

    By Updated April 24, 2024
  • An image of a neural cell, colored red, is seen on a black background.
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Neurocrine scores surprise win with depression drug

    Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.

    By April 23, 2024
  • An Ipsen site in Wrexham, UK.
    Image attribution tooltip
    Courtesy of Ipsen
    Image attribution tooltip

    Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases

    The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA. 

    By April 22, 2024
  • Photo of Takeda Pharmaceutical's global headquarters in Japan.
    Image attribution tooltip
    Courtesy of Takeda Pharmaceuticals
    Image attribution tooltip

    Pharmas form joint venture to jumpstart Japanese drug research

    A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.

    By April 22, 2024
  • A person sits in an office chair next to a sign reading Cerevel.
    Image attribution tooltip
    Permission granted by Cerevel Therapeutics
    Image attribution tooltip

    Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study

    Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech.

    By April 18, 2024
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Emerging biotech

    Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

    It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company acquired a portfolio of medicines it aims to test in combination.

    By April 18, 2024
  • An illustration of two neurons, colored blue and purple
    Image attribution tooltip
    noparrit via Getty Images
    Image attribution tooltip

    Sage’s cognition drug fails in Parkinson’s study

    Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.

    By April 17, 2024
  • A portrait of Uwe Schoenbeck at Canaan Partners.
    Image attribution tooltip
    Permission granted by Canaan
    Image attribution tooltip

    Canaan hires Pfizer executive, reels in $100M for biotech investing

    The firm has brought in as venture partner Uwe Schoenbeck, who most recently was the top scientist for Pfizer’s emerging science and innovation unit.

    By April 17, 2024
  • An illustration of antibodies attacking a nerve cell.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Cullinan changes name, pivots to autoimmune disease

    The biotech says a dual-pronged antibody it’s developing could become an “off-the-shelf” alternative to cell therapies in development for lupus and other inflammatory conditions.

    By Kristin Jensen • April 16, 2024
  • Two people in white coats work at a laboratory benchtop.
    Image attribution tooltip
    Courtesy of Alexandria Real Estate Equities
    Image attribution tooltip
    Q&A // Emerging biotech

    Biotech landlord Alexandria on research clusters and the sector’s recovery

    Joel Marcus, the longtime head of Alexandria Real Estate Equities, sees few near-term challengers to the established biotech hubs of Boston, San Diego and San Francisco.

    By April 16, 2024
  • Neumora CEO Henry Gosebruch stands for a photo against a blurred office background
    Image attribution tooltip
    Permission granted by Neumora Therapeutics
    Image attribution tooltip

    Neumora’s schizophrenia drug hit with clinical hold

    Shares of the biotech dipped by double digits following disclosure the FDA had paused an early-stage study of Neumora’s muscarinic-targeting drug.

    By April 15, 2024